146 related articles for article (PubMed ID: 8722423)
21. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
22. Biodistribution of anti-breast mucin HuBrE3-derived inverted Fabs (IFabs) in nude mice carrying MX-1 xenografts.
Speck RR; Blank EW; Couto JR
Hybridoma; 1997 Jun; 16(3):243-8. PubMed ID: 9219034
[TBL] [Abstract][Full Text] [Related]
23. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.
Fielding SL; Flower MA; Ackery D; Kemshead JT; Lashford LS; Lewis I
Eur J Nucl Med; 1991; 18(5):308-16. PubMed ID: 1936038
[TBL] [Abstract][Full Text] [Related]
24. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin.
Desrues B; Léna H; Brichory F; Ramée MP; Toujas L; Delaval P; Dazord L
Br J Cancer; 1995 Nov; 72(5):1076-82. PubMed ID: 7577450
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
28. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
29. New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
Mairs RJ; Zalutsky MR
Br J Cancer; 1995 Jul; 72(1):250. PubMed ID: 7599061
[No Abstract] [Full Text] [Related]
30. The treatment of neuroblastoma with 131I-MIBG.
Mastrangelo R
Med Pediatr Oncol; 1987; 15(4):157-8. PubMed ID: 3657703
[No Abstract] [Full Text] [Related]
31. Radiolabelled mIBG in the treatment of neuroblastoma.
Gaze MN; Wheldon TE
Eur J Cancer; 1996 Jan; 32A(1):93-6. PubMed ID: 8695251
[No Abstract] [Full Text] [Related]
32. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.
Ugur O; Scott AM; Kostakoglu L; Hui TE; Masterson ME; Febo R; Sgouros G; Rosa E; Mehta BM; Fisher DR
Nucl Med Biol; 1995 Jan; 22(1):87-93. PubMed ID: 7735175
[TBL] [Abstract][Full Text] [Related]
33. The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription.
Fielding SL; Flower MA; Ackery DM; Kemshead J; Lashford LS; Lewis IJ
Radiother Oncol; 1992 Sep; 25(1):73-6. PubMed ID: 1410594
[TBL] [Abstract][Full Text] [Related]
34. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates.
Hopkins K; Papanastassiou V; Kemshead JT
Recent Results Cancer Res; 1996; 141():159-75. PubMed ID: 8722426
[No Abstract] [Full Text] [Related]
35. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.
Cheung NK; Landmeier B; Neely J; Nelson AD; Abramowsky C; Ellery S; Adams RB; Miraldi F
J Natl Cancer Inst; 1986 Sep; 77(3):739-45. PubMed ID: 3091900
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Nucl Med Biol; 1996 Aug; 23(6):851-6. PubMed ID: 8940730
[TBL] [Abstract][Full Text] [Related]
37. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.
Lashford LS; Moyes J; Ott R; Fielding S; Babich J; Mellors S; Gordon I; Evans K; Kemshead JT
Eur J Nucl Med; 1988; 13(11):574-7. PubMed ID: 3350034
[TBL] [Abstract][Full Text] [Related]
38. Biodistribution of iodine-125 labeled monoclonal antibody/interleukin-2 immunoconjugate in athymic mice bearing human tumor xenografts.
Nakamura K; Kubo A
Cancer; 1997 Dec; 80(12 Suppl):2650-5. PubMed ID: 9406720
[TBL] [Abstract][Full Text] [Related]
39. Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine.
Sisson JC; Hutchinson RJ; Carey JE; Shapiro B; Johnson JW; Mallette SA; Wieland DM
Eur J Nucl Med; 1988; 14(7-8):337-40. PubMed ID: 3181182
[TBL] [Abstract][Full Text] [Related]
40. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
